You are here: Industry Insights > I-Mab

News List

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 prnasia
May 20, 2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that an abstract detailing clinical data from its U.S. phase 1 study of uliledlimab in combination with ...
I-Mab Announces Upcoming Participation at May Conferences I-Mab
May 17, 2021
I-Mab announces its participation in the following conferences in May.
Shanghai Genechem Co., Ltd. (Genechem) Announces Global Collaboration on Bispecific Antibodies prnasia
April 07, 2021
Shanghai Genechem Co., Ltd., a discovery company dedicated to novel drug target discovery and development of novel therapeutics, announced the execution of a global collaboration with I-Mab, a Nasdaq-listed global biopharmaceutical company, to develop ...
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S. prnasia
February 07, 2021
I-Mab announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody, uliledlimab (also known as TJD5, or TJ004309) in advanced solid tumors.
I-Mab, MorphoSys Announce First Patient Dosed in Study of TJ210/MOR210 for Advanced Cancer americanpharmaceuticalreview
February 02, 2021
I-Mab and MorphoSys announced the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with relapsed or refractory ...
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer prnasia
January 26, 2021
I-Mab, and MorphoSys today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with relapsed ...
I-Mab Added to Nasdaq Biotechnology Index prnasia
December 15, 2020
I-Mab announced that I-Mab's American Depositary Shares (ADS) have been selected for inclusion in the NASDAQ Biotechnology Index, based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020.
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China prnasia
December 07, 2020
I-Mab announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the US and China, achieving milestones as planned.
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board prnasia
December 02, 2020
I-Mab announced the strengthening of its Scientific Advisory Board with the appointment of leading international experts Dr. Chen Dong and Dr. Jun Ma.
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020 prnasia
November 12, 2020
I-Mab announced new preclinical data from in vivo and in vitro studies of its C5aR antibody project, TJ210/MOR210, at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Previous page 1 2 3 4 5 6 Next page